125
Views
9
CrossRef citations to date
0
Altmetric
Letter to the Editor

Update on bipolar disorder biomarker candidates: what about uric acid/adenosine hypothesis?

, &
Pages 105-106 | Received 28 Oct 2016, Accepted 07 Dec 2016, Published online: 16 Dec 2016

References

  • Teixeira AL, Salem H, Frey BN, et al. Update on bipolar disorder biomarker candidates. Expert Rev Mol Diagn. 2016;16:1209–1220. DOI:10.1080/14737159.2016.1248413
  • Machado-Vieira R, Lara DR, Souza DO, et al. Purinergic dysfunction in mania: an integrative model. Med Hypotheses. 2002;58(4):297–304.
  • Albert U, De Cori D, Aguglia A, et al. Increased uric acid levels in bipolar disorder subjects during different phases of illness. J Affect Disord. 2015;173:170–175.
  • Hirota T, Kishi T. Adenosine hypothesis in schizophrenia and bipolar disorder: a systematic review and meta-analysis of randomized controlled trial of adjuvant purinergic modulators. Schizophr Res. 2013;149(1–3):88–95.
  • Muti M, Del Grande C, Musetti L, et al. Serum uric acid levels and different phases of illness in bipolar I patients treated with lithium. Psychiatry Res. 2015;225(3):604–608.
  • Grassi D, Ferri L, Desideri G, et al. Chronic hyperuricemia, uric acid deposit and cardiovascular risk. Curr Pharm Des. 2013;19(13):2432–2438.
  • Abbracchio MP, Burnstock G, Verkhratsky A, et al. Purinergic signaling in the nervous system: an overview. Trends Neurosci. 2009;32(1):19–29.
  • Burnstock G. Physiology and pathophysiology of purinergic neurotransmission. Physiol Rev. 2007;87(2):659–797.
  • Burnstock G. Purinergic signalling and disorders of the central nervous system. Nat Rev Drug Discov. 2008;7(7):575–590.
  • Burnstock G, Fredholm BB, Verkhratsky A. Adenosine and ATP receptors in the brain. Curr Top Med Chem. 2011;11(8):973–1011.
  • Krügel U. Purinergic receptors in psychiatric disorders. Neuropharmacology. 2016;104:212–225.
  • Gomes CV, Kaster MP, Tomé AR, et al. Adenosine receptors and brain diseases: neuroprotection and neurodegeneration. Biochim Biophys Acta. 2011;1808(5):1380–1399.
  • Lindberg D, Shan D, Ayers-Ringler J, et al. Purinergic signaling and energy homeostasis in psychiatric disorders. Curr Mol Med. 2015;15(3):275–295.
  • Ortiz R, Ulrich H, Zarate CA Jr, et al. Purinergic system dysfunction in mood disorders: a key target for developing improved therapeutics. Prog Neuropsychopharmacol Biol Psychiatry. 2015;57:117–131.
  • Machado-Vieira R, Soares JC, Lara DR, et al. A double-blind, randomized, placebo-controlled 4-week study on the efficacy and safety of the purinergic agents allopurinol and dipyridamole adjunctive to lithium in acute bipolar mania. J Clin Psychiatry. 2008;69(8):1237–1245.
  • Machado-Vieira R. Purinergic system in the treatment of bipolar disorder: uric acid levels as a screening test in mania. J Clin Psychopharmacol. 2012;32(5):735–736.
  • Sutin AR, Cutler RG, Camandola S, et al. Impulsivity is associated with uric acid: evidence from humans and mice. Biol Psychiatry. 2014;75(1):31–37.
  • Lorenzi TM, Borba DL, Dutra G, et al. Association of serum uric acid levels with emotional and affective temperaments. J Affect Disord. 2010;121(1–2):161–164.
  • Akhondzadeh S, Milajerdi MR, Amini H, et al. Allopurinol as an adjunct to lithium and haloperidol for treatment of patients with acute mania: a double-blind, randomized, placebo-controlled trial. Bipolar Disord. 2006;8(5 Pt 1):485–489.
  • Fan A, Berg A, Bresee C, et al. Allopurinol augmentation in the outpatient treatment of bipolar mania: a pilot study. Bipolar Disord. 2012;14(2):206–210.
  • Jahangard L, Soroush S, Haghighi M, et al. In a double-blind, randomized and placebo-controlled trial, adjuvant allopurinol improved symptoms of mania in in-patients suffering from bipolar disorder. Eur Neuropsychopharmacol. 2014;24(8):1210–1221.
  • Weiser M, Burshtein S, Gershon AA, et al. Allopurinol for mania: a randomized trial of allopurinol versus placebo as add-on treatment to mood stabilizers and/or antipsychotic agents in manic patients with bipolar disorder. Bipolar Disord. 2014;16(4):441–447.
  • Bartoli F, Crocamo C, Clerici M, et al. Allopurinol as add-on treatment for mania symptoms in bipolar disorder: a systematic review and meta-analysis of randomised controlled trials. Br J Psychiatry. 2016. DOI:10.1192/bjp.bp.115.180281
  • Bartoli F, Crocamo C, Mazza MG, et al. Uric acid levels in subjects with bipolar disorder: a comparative meta-analysis. J Psych Res. 2016;81:133–139.
  • Bartoli F, Crocamo C, Gennaro GM, et al. Exploring the association between bipolar disorder and uric acid: a mediation analysis. J Psychosom Res. 2016;84:56–59.
  • Bartoli F, Crocamo C, Dakanalis A, et al. Purinergic system dysfunctions in subjects with bipolar disorder: a comparative cross-sectional study. Compr Psychiatry. 2016. DOI:10.1016/j.comppsych.2016.09.011
  • Kapczinski F, Dal-Pizzol F, Teixeira AL, et al. A systemic toxicity index developed to assess peripheral changes in mood episodes. Mol Psychiatry. 2010;15(8):784–786.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.